

Structural Analysis of Predicted HIV-1 Secis Elements

Paushali Roy*, Sayak Ganguli, Pooja Sharma, Protip Basu, Abhijit Datta

DBT Centre for Bioinformatics, Presidency University, Kolkata, India.
E-mail: *paushali.06@gmail.com

Received August 30th, 2011; revised October 6th, 2011; accepted October 19th, 2011.

ABSTRACT

Incorporation of Selenocysteine into protein requires an RNA structural motif, SECIS (Selenocysteine insertion sequence) element that, along with other factors, demarcates UGA-Sec from the UGA termination codon, for expression of Selenoproteins (in case of eukaryotes). It has been predicted that during HIV infection, several functional viral selenoproteins are expressed and synthesis of these viral selenoproteins deplete the selenium level of the host. It might be that even the viral genome has the SECIS elements in their Selenoprotein mRNA, and during infection, the host cellular machinery is transformed in such a way that the human Sec tRNA binds to the viral Selenoprotein mRNA, instead of binding to its own Selenoprotein mRNA, thus leading to expression of viral selenoproteins. This hypothesis was tested in this study by identifying the SECIS elements in the HIV-1 genome and further predicting their secondary and tertiary structures. We then tried to dock these tertiary structures with human Sec tRNA. Here we report putatively the presence of 3215 SECIS elements in the HIV-1 genome and that the human Sec tRNA^{sec} binds to the viral SECIS elements present in the viral selenoprotein mRNA. Based on an earlier finding, it was observed that atoms of A8 and U9, which present in human Sec tRNA, are the possible key sites for binding.

Keywords: Selenocysteine, Selenium, SECIS Element, Selenoprotein, Human Sec tRNA^{sec}, UGA Codon

1. Introduction

Selenium, an essential micronutrient, is a natural component of selenium dependent enzymes, and in most of these it occurs in the amino acid selenocysteine, that is present in the catalytic centers of the proteins [1]. These selenium dependent enzymes called selenoproteins include one or more Selenocysteine residues, where selenium acts an antioxidant [2]. Selenium plays an important role in the proper functioning of the immune system and inhibiting the progression of HIV infection to AIDS. It is required for the activity of the enzyme glutathione peroxidase, and deficiency in selenium may cause myopathy, cardiomyopathy and immune dysfunction [3].

Selenoproteins such as glutathione peroxidases, thio-redoxin reductases, and iodothyronine deiodinases are involved in redox reactions [4]. At the physiological level, these enzymes are involved in diverse metabolic and physiological functions ranging from antioxidant defense to fertility, muscle development and function, thyroid hormone metabolism, and immune function [5].

Expression of the selenoproteins requires the incorporation and biosynthesis of the amino acid Selenocysteine

(reviewed in Atkins & Gesteland, 2000). Selenocysteine is the 21st amino acid in the genetic code and is encoded by the codon UGA that is generally a termination codon. Certain factors have been found in eukaryotes that mediate the biosynthesis of Selenocysteine and thus the expression of selenoproteins [6,7]. One of the major factor are the SECIS elements, an RNA structural motif, that have been found in the 3' UTR of the eukaryotic selenoprotein mRNA.

The 3' and 5' untranslated regions of the HIV-1 genome have all the RNA motifs concentrated within it, these include internal ribosome entry sites, packaging signals, pseudoknots, transfer RNA mimics, ribosomal frameshift motifs, and cis-regulatory elements [8,9]. In the human immunodeficiency virus (HIV), RNA structures activate transcription, initiate reverse transcription, facilitate genomic dimerization, direct HIV packaging, manipulate reading frames, regulate RNA nuclear export, signal polyadenylation, and interact with viral and host proteins [9-13]. Most potential regulatory structures within the HIV-1 genome are uncharacterized raising the possibility of new RNA structure-mediated regulation to be identified [14].

It has been reported that during HIV infection the level of selenium in the host, decreases and expression of viral selenoproteins increases. Also, it has been proposed that HIV-1 may encode several selenoproteins one of which has significant sequence similarity to GPx that is a mammalian selenoprotein [15].

Selenocysteine insertion sequence (SECIS) element has not yet been identified in the HIV genome by either biologic or computational methods. Sequence analysis has identified locations in HIV-1 strain HXB2 where SECIS element could exist [16].

The aim of this study is to identify the plausible SECIS elements in the HIV-1 genome and deduce their role in the deficiency of selenium and increased expression of viral selenoproteins during HIV infection.

The results obtained showed that, indeed there are SECIS elements present in the HIV-1 genome and the human Sec tRNA^{Sec} binds to the viral selenoprotein mRNA, wherein possibly the key residues are the atoms of A8 and U9 which are involved in stability of the binding.

We hypothesize that during HIV infection when translation occurs, the human Selenocysteine tRNA^{Sec} binds to the viral selenoprotein mRNA that has the presence of SECIS elements. Thus Selenocysteine would get incorporated in the growing polypeptide chain, utilizing the host's selenium, and will lead to the expression of viral selenoproteins instead of human selenoproteins.

2. Methods

We first retrieved 847 complete genome sequences of the HIV-1 genome from the NCBI database. The RNA regulatory motifs for all these sequences were then obtained using a stacking energy thermodynamic model based on Bayesian statistics for identifying the homologs of Regulatory RNA motifs and elements against an input mRNA sequence. The full process of a typical Bayesian analysis can be roughly described as consisting of three main steps: 1) setting up a full probability model that includes all the variables so as to capture the relationship among these variables; 2) summarizing the findings for particular interests by appropriate posterior distributions; 3) evaluating the appropriateness of the model and suggesting improvements [17].

A standard procedure for carrying out step 1) is to first write down the likelihood function, *i.e.*, the probability of the observed data given the unknowns, and multiply it by a prior distribution, *i.e.*, a distribution for all the unobserved variables (typically unknown parameters). The joint probability is represented as joint = likelihood prior, *i.e.*,

$$p(y, \theta) = p(y|\theta)p(\theta)$$

where the prior distribution reveals what is known about the parameter without the knowledge of the data. Bayesian inference is drawn by examining the probability of all possible values of the parameter after considering the data. Accordingly, step 2) is completed by obtaining the posterior distribution:

$$p(\theta|y) = \frac{p(\theta|y)}{p(y)} = \frac{p(y|\theta)p(\theta)}{p(y)} \propto p(y|\theta)p(\theta)$$

where the posterior distribution tells us what is known about y given knowledge of the data.

Both sequence homologs and structural homologs of regulatory RNA motifs could be identified. In this work the basic focus was on the RNA structural motif named SECIS (Selenocysteine Insertion Sequence) element.

Our next *in-silico* experiment was performed on the same set of HIV-1 genome sequences to specifically identify the SECIS elements, if present, in the genome. This was done using a computational tool based on a SECIS consensus model the key feature of which is a conserved guanosine in a small apical loop of the properly positioned structure [18].

Using the sequences of the SECIS elements obtained, we designed their secondary structures based on the RNA secondary structure (folding) prediction algorithm given by M.Zuker. The algorithm predicts the possible secondary structures based on minimum free energy (ΔG) criterion. We arranged the secondary structures according to increasing free energies (a negative quantity), and selected the first 20 which had the least free energy values.

As we had hypothesized, our next experiment was to see whether the human Selenocysteine tRNA binds to the viral selenoprotein mRNA. For this the tertiary structures of the above 20 secondary structures were designed using computational tools. Human selenocysteine tRNA sequence was obtained from NCBI and secondary structure is designed. The tertiary structure of human Selenocysteine tRNA was obtained from PDB (PDB id 3A3A). We then tried to dock them individually, *i.e.* we performed twenty dockings, with the 20 tertiary structures of SECIS elements as receptor and human Selenocysteine tRNA as the ligand.

In the last part of our work, we removed the residues A8 and U9 from the tertiary structure of human Selenocysteine tRNA and performed the dockings again. The new docking results were compared with the earlier docking results.

3. Results and Discussion

The 3' untranslated region of all the sequences showed the presence of SECIS elements (**Table 1**).

Table 1. Motifs found in 3' UTR of HIV-1 genome sequences.

Strain	Secis Type-1	Strain	Secis Type-1
gi 217038387 gb FJ460501.1 HIV-1 isolate HK004 from Hong Kong, complete genome	✓	gi 170878295 gb EU541617.1 HIV-1 clone pIIIB from USA, complete genome	✓
gi 13540181 gb AF289550.1 HIV-1 clone 96TZ-BF110 from Tanzania, complete genome	✓	gi 161334695 gb EU220698.1 HIV-1 isolate 04CA7750 from Canada, complete genome	✓
gi 167651353 gb EU293450.1 HIV-1 isolate 99ZALT46 from South Africa, complete genome	✓	gi 117940228 gb DQ912823.1 HIV-1 isolate MA from Denmark, complete genome	✓
gi 213495604 gb FJ195091.1 HIV-1 isolate BREPM1081 from Brazil, complete genome	✓	gi 168208535 gb EU448296.1 HIV-1 strain 06FR-CRN from France, complete genome	✓
gi 212674726 gb EU884501.1 HIV-1 isolate ES P1423 (CRF02_AG) from Spain, complete genome	✓	gi 164415926 gb DQ020274.2 HIV-1 isolate CB134 from Cuba, complete genome	✓
gi 195409392 gb EU697909.1 HIV-1 isolate J11456 from Saudi Arabia, complete genome	✓	gi 157885655 gb EU031915.1 HIV-1 isolate 07MYKLD49 from Malaysia, complete genome	✓
gi 83026775 gb DQ295192.1 HIV-1 isolate 04LSK7 from South Korea, complete genome	✓	gi 125541773 gb EF192591.1 HIV-1 isolate CU-98-26 from Thailand, complete genome	✓
gi 197257781 gb EU693240.1 HIV-1 isolate 06CM-BA-040 from Cameroon, complete genome	✓	gi 85035359 gb DQ230841.1 HIV-1 isolate TW_D3 from Taiwan, complete genome	✓
gi 194500414 gb EU861977.1 HIV-1 isolate 60000 from Italy, complete genome	✓	gi 117643970 gb EF029069.1 HIV-1 isolate U.NL.01.H10986_C11 from Netherlands, complete genome	✓
gi 209156839 gb FJ213780.1 HIV-1 isolate UY05_4752 from Uruguay, complete genome	✓	gi 51980229 gb AY612637.1 HIV-1 isolate PT2695 from Portugal, complete genome	✓
gi 2944126 gb U71182.1 HIVU71182 HIV-1 isolate RL42 from China, complete genome	✓	gi 112497950 gb DQ676887.1 HIV-1 isolate PS4048_Day143 from Australia, complete genome	✓
gi 158967436 gb EU110097.1 HIV-1 isolate ML1990PCR from Kenya, complete genome	✓	gi 63081177 gb AY968312.1 HIV-1 isolate ARE195FL from Argentina, complete genome	✓
gi 6651466 gb AF193277.1 HIV-1 isolate RU98001 from Russia, complete genome	✓	gi 18643009 gb AY074891.1 HIV-1 isolate 00BWMO35.1 from Botswana, complete genome	✓
gi 3947925 gb AF049337.1 HIV-1 CRF04_cpx clone 94CY032-3 from Cyprus, complete genome	✓	gi 74099684 gb DQ083238.1 HIV-1 isolate 1579A from India, complete genome	✓
gi 62361768 gb AY882421.1 HIV-1 isolate 9196/01 from Germany, complete genome	✓	gi 29409304 gb AY093604.1 HIV-1 isolate 95SN7808 from Senegal, complete genome	✓
gi 18699247 gb AF414006.1 HIV-1 isolate 98BY10443 from Belarus, complete genome	✓	gi 47118239 gb AY536235.1 HIV-1 isolate CH12 from Chile, complete genome	✓
gi 18699185 gb AF413987.1 HIV-1 isolate 98UA0116 from Ukraine, complete genome	✓	gi 47118229 gb AY536236.1 HIV-1 isolate V62 from Venezuela, complete genome	✓
gi 6466838 gb AF184155.1 HIV-1 G829 from Ghana complete genome	✓	gi 38679157 gb AY352657.1 HIV-1 isolate UG266 from Uganda, complete genome	✓
gi 56131599 gb AY805330.1 HIV-1 isolate HIV1084i from Zambia, complete genome	✓	gi 38679140 gb AY352655.1 HIV-1 isolate SE9010 from Sweden, complete genome	✓
gi 6690753 gb AF197341.1 HIV-1 isolate 90CF4071 from Central African Republic, complete genome	✓	gi 14530226 gb AF286236.1 AF286236 HIV-1 isolate 83CD003 from Republic of the Congo, complete genome	✓
gi 17352343 gb AY046058.1 HIV-1 from Greece, complete genome	✓	gi 3779261 gb AF064699.1 AF064699 HIV-1 isolate BFP90 from Burkina Faso, complete genome	✓
gi 13569307 gb AF286233.1 AF286233 HIV-1 strain 98IS002 from Israel, complete genome	✓	gi 5668910 gb AF076474.1 AF076474 HIV-1 isolate VI354 from Gabon, complete genome	✓
gi 6090965 gb AF075703.1 AF075703 HIV-1 isolate FIN9363 subtype F1 from Finland, complete genome	✓	-	-

This result thus confirmed putatively, to some extent, that SECIS elements may be present in the HIV genome. Other motifs were also obtained *i.e.* K-Box, GY-Box, Gamma interferon activated inhibitor of Ceruloplasmin mRNA translation (GAIT element), Brd-Box, Cytoplas-

mic polyadenylation element, Alcohol dehydrogenase 3'UTR down regulation control element (ADH_DRE), Mos polyadenylation response element (Mos-PRÉ), Androgen receptor CU-rich element (AR_CURE) in the 3' UTR and those in the 5' UTR are Terminal Oligo-

pyrimidine Tract (TOP), Internal Ribosome Entry Site (IRES), Upstream Open Reading Frame (uORF). Exonic regulatory motifs, transcriptional regulatory motifs, miRNA target sites and RNA structural elements were also found, (see **Table 2**).

The presence of Selenocysteine insertion sequence (SECIS) elements has been confirmed in eukaryotes (including humans). In eukaryotes, SECIS elements are required for the expression of selenoproteins. Functional selenoproteins, similar to mammalian selenoproteins, have been found in the HIV-1 genome. Based on these already proven theories it was thought that, the HIV genome may contain SECIS elements and this was confirmed by performing a search for SECIS elements on all

the 847 complete genome sequences of the HIV-1 genome. The number of SECIS elements obtained putatively was variable for each sequence. The total number of SECIS elements obtained was 3215.

Since lower free energy value means a highly stable structure, so out of the 3215 structures 25 most stable predicted structures were selected (see **Figure 1**).

The sequence of Human selenocysteine tRNA was retrieved from PDB (>3A3A:A|PDBID|CHAIN|SEQUENCEGCCCGGAUGAUCCUCAGUGGUCUGGGGUGC-AGGCUUCAACCUGUAGCUGUCUAGCGACAGAGUGGUUCAAUUCCACCUUUCGGGCGCCA) and its corresponding secondary structure was designed by application of RNA covariance models, which are general,

Table 2. Motifs found in regions other than 3' and 5'UTR.

Strain	Exonic Regulatory Motifs	Transcriptional Regulatory Motifs	miRNA Target Sites	RNA Structural Elements
gi 217038387 gb FJ460501.1 HIV-1 isolate HK004 from Hong Kong, complete genome	54	17	111	
gi 13540181 gb AF289550.1 HIV-1 clone 96TZ-BF110 from Tanzania, complete genome	53	18	89	
gi 167651353 gb EU293450.1 HIV-1 isolate 99ZALT46 from South Africa, complete genome	52	21	97	
gi 213495604 gb FJ195091.1 HIV-1 isolate BREPM1081 from Brazil, complete genome	54	19	109	1
gi 212674726 gb EU884501.1 HIV-1 isolate ES P1423 (CRF02_AG) from Spain, complete genome	47	19	93	
gi 195409392 gb EU697909.1 HIV-1 isolate J11456 from Saudi Arabia, complete genome	42	17	104	
gi 83026775 gb DQ295192.1 HIV-1 isolate 04LSK7 from South Korea, complete genome	47	20	108	
gi 197257781 gb EU693240.1 HIV-1 isolate 06CM-BA-040 from Cameroon, complete genome	48	16	88	
gi 194500414 gb EU861977.1 HIV-1 isolate 60000 from Italy, complete genome	51	19	96	
gi 209156839 gb FJ213780.1 HIV-1 isolate UY05_4752 from Uruguay, complete genome	49	16	89	
gi 2944126 gb U71182.1 HIVU71182 HIV-1 isolate RL42 from China, complete genome	56	17	103	
gi 158967436 gb EU110097.1 HIV-1 isolate ML1990PCR from Kenya, complete genome	53	18	75	
gi 6651466 gb AF193277.1 HIV-1 isolate RU98001 from Russia, complete genome	57	16	96	
gi 3947925 gb AF049337.1 HIV-1 CRF04_cpx clone 94CY032-3 from Cyprus, complete genome	56	18	105	
gi 170878295 gb EU541617.1 HIV-1 clone pIIIB from USA, complete genome	61	21	100	
gi 161334695 gb EU220698.1 HIV-1 isolate 04CA7750 from Canada, complete genome	51	16	94	
gi 117940228 gb DQ912823.1 HIV-1 isolate MA from Denmark, complete genome	54	19	93	
gi 168208535 gb EU448296.1 HIV-1 strain 06FR-CRN from France, complete genome	52	25	88	

gi 164415926 gb DQ020274.2 HIV-1 isolate CB134 from Cuba, complete genome	42	20	105	
gi 157885655 gb EU031915.1 HIV-1 isolate 07MYKLD49 from Malaysia, complete genome	51	17	96	
gi 125541773 gb EF192591.1 HIV-1 isolate CU-98-26 from Thailand, complete genome	50	24	95	
gi 85035359 gb DQ230841.1 HIV-1 isolate TW_D3 from Taiwan, complete genome	52	22	91	
gi 117643970 gb EF029069.1 HIV-1 isolate U.NL.01.H10986_C11 from Netherlands, complete genome	51	19	89	
gi 51980229 gb AY612637.1 HIV-1 isolate PT2695 from Portugal, complete genome	39	19	107	
gi 112497950 gb DQ676887.1 HIV-1 isolate PS4048_Day143 from Australia, complete genome	51	19	78	
gi 63081177 gb AY968312.1 HIV-1 isolate ARE195FL from Argentina, complete genome	57	24	102	
gi 18643009 gb AY074891.1 HIV-1 isolate 00BWMO35.1 from Botswana, complete genome	54	20	109	
gi 23986250 gb AY049711.1 HIV-1 isolate 01IN565.14 from India, complete genome	51	18	95	
gi 46243163 gb AY535660.1 HIV-1 isolate EE0369 from Estonia, complete genome	54	18	102	
gi 62361768 gb AY882421.1 HIV-1 isolate 9196/01 from Germany, complete genome	47	19	85	
gi 18699247 gb AF414006.1 HIV-1 isolate 98BY10443 from Belarus, complete genome	55	17	104	
gi 18699185 gb AF413987.1 HIV-1 isolate 98UA0116 from Ukraine, complete genome	47	19	99	1
gi 6466838 gb AF184155.1 HIV-1 G829 from Ghana complete genome	47	20	87	
gi 56131599 gb AY805330.1 HIV-1 isolate HIV1084i from Zambia, complete genome	50	21	100	
gi 29409304 gb AY093604.1 HIV-1 isolate 95SN7808 from Senegal, complete genome	53	26	90	
gi 47118239 gb AY536235.1 HIV-1 isolate CH12 from Chile, complete genome	47	18	94	1
gi 47118229 gb AY536236.1 HIV-1 isolate V62 from Venezuela, complete genome	50	17	103	
gi 38679157 gb AY352657.1 HIV-1 isolate UG266 from Uganda, complete genome	57	21	100	
gi 38679131 gb AY352654.1 HIV-1 isolate SE8646 from Sweden, complete genome	43	19	101	
gi 6690753 gb AF197341.1 HIV-1 isolate 90CF4071 from Central African Republic, complete genome	50	22	93	
gi 17352343 gb AY046058.1 HIV-1 from Greece, complete genome	55	22	84	
gi 14530226 gb AF286236.1 AF286236 HIV-1 isolate 83CD003 from Republic of the Congo, complete genome	54	18	107	
gi 3779261 gb AF064699.1 AF064699 HIV-1 isolate BFP90 from Burkina Faso, complete genome	50	12	91	
gi 13569307 gb AF286233.1 AF286233 HIV-1 strain 98IS002 from Israel, complete genome	53	24	85	
gi 6090965 gb AF075703.1 AF075703 HIV-1 isolate FIN9363 subtype F1 from Finland, complete genome	45	18	99	
gi 5668910 gb AF076474.1 AF076474 HIV-1 isolate VI354 from Gabon, complete genome	50	16	94	



Figure 1. Predicted secondary structures of SECIS elements.

probabilistic secondary structure profiles based on stochastic context-free grammars (see **Figure 2**).

The tertiary structures of all the 20 SECIS elements showed a similar kind of a structure, (see **Figure 3**).

These were docked to the crystal structure of human Selenocysteine tRNA (see **Figure 4**).

Also known is the fact that during HIV infection selenium pool of the host gets depleted and viral selenoproteins increase. During translation, the tRNA binds to the mRNA (at the corresponding codon) for the expression of the protein. Human Selenocysteine tRNA (tRNA^{Sec}) has an anticodon complementary to the UGA codon. If the human Selenocysteine tRNA binds to the viral mRNA that has the SECIS elements, then the viral selenoproteins might get expressed and this may be the probable cause of the increase in viral selenoproteins and depletion of host selenium, as it is being used up by the viral genome. So, the human Selenocysteine tRNA, instead of getting attached to its own selenoprotein mRNA,




Figure 2. Predicted secondary structure of human selenocysteine tRNA.




Figure 3. Predicted tertiary structures of SECIS elements.

attaches to the viral selenoprotein mRNA during HIV infection. The docking results confirmed this putatively as the free energy values of the 20 docked complexes (see **Figure 5**) were very low, hence the binding was


highly stable.

The docked complexes were clustered according to E-values and country (**Table 3**).

The D stem and the extra arm do not form tertiary in-

Table 3. Clustering according to E-values and country.

Sequence Details	E Total
>gi 217038387 gb FJ460501.1 HIV-1 isolate HK004 from Hong Kong, complete genome	-26049.78
>gi 217038377 gb FJ460500.1 HIV-1 isolate HK003 from Hong Kong, complete genome	-24043.97
>gi 217038367 gb FJ460499.1 HIV-1 isolate HK002 from Hong Kong, complete genome	-27350.14
>gi 167651343 gb EU293449.1 HIV-1 isolate 99ZALT45 from South Africa, complete genome	-37608.79
>gi 149939408 gb EF633445.1 HIV-1 isolate R1 from South Africa, complete genome	-29866.54
>gi 63098379 gb DQ011175.1 HIV-1 isolate 03ZASK005B2 from South Africa, complete genome	-19193.88
>gi 63098294 gb DQ011166.1 HIV-1 isolate 04ZASK135B1 from South Africa, complete genome	-20754.28
>gi 85700643 gb DQ351234.1 HIV-1 isolate 03ZASK233B1 from South Africa, complete genome	-15853.64
>gi 85700503 gb DQ351220.1 HIV-1 isolate 02ZAPS006MB1 from South Africa, complete genome	-29420.57
>gi 68522063 gb DQ093598.1 HIV-1 isolate 04ZAPS202B1 from South Africa, complete genome	-16265.70
>gi 51572093 gb AY703908.1 HIV-1 isolate 03ZASK040B1 from South Africa, complete genome	-15903.14
>gi 46486663 gb AY585268.1 HIV-1 isolate C.ZA.1069MB from South Africa, complete genome	-29545.00
>gi 57338555 gb AY838567.1 HIV-1 isolate 1069MB from South Africa, complete genome	-16336.54
>gi 24181477 gb AF411964.1 HIV-1 isolate 99ZACM4 from South Africa, complete genome	-34332.66
>gi 29119285 gb AY173954.1 HIV-1 isolate US3 from USA, complete genome	-22281.61
>gi 37677763 gb AY331283.1 HIV-1 isolate 1001-09 from USA, complete genome	-30852.84
>gi 37677753 gb AY331282.1 HIV-1 isolate 1001-07 from USA, complete genome	-18468.71
>gi 55735993 gb AY771593.1 HIV-1 isolate BREPM278 from Brazil, complete genome	-27615.47
>gi 55735957 gb AY771589.1 HIV-1 isolate BREPM108 from Brazil, complete genome	-17908.92
>gi 157274079 gb EF637057.1 HIV-1 isolate BREPM1023 from Brazil, complete genome	-38704.25
>gi 157274021 gb EF637051.1 HIV-1 isolate BREPM1032 from Brazil, complete genome	-16073.70
>gi 157274001 gb EF637049.1 HIV-1 isolate BREPM1035 from Brazil, complete genome	-21868.21
>gi 86277616 gb DQ358809.1 HIV-1 isolate 02BR011 from Brazil, complete genome	-44666.35
>gi 221474 dbj D10112.1 HIVCAM1 Human immunodeficiency virus 1 proviral DNA, complete genome	-32795.28

**Figure 4. Predicted crystal structure of human selenocysteine tRNA.**

teractions in tRNA^{Sec}. Rather, tRNA^{Sec} has an open cavity, in place of the tertiary core of a canonical tRNA. The linker residues, A8 and U9, connecting the acceptor and D stems, are not involved in tertiary base pairing. Instead, U9 is stacked on the first base pair of the extra arm. These features might allow tRNA^{Sec} to be the target of the Selenocysteine synthesis/incorporation machineries. Following this finding, the residues A8 and U9 were removed from the structure of human selenocysteine tRNA and this was docked with the SECIS element (one from Group-3). The atoms of the residues have been highlighted (see **Figure 6**) and the bond between the SECIS element and the residues is shown (see **Figure 7**).




Figure 5. Predicted 20 docked complexes.

The result showed an increase in the E-value *i.e.* the free energy, hence a less stable structure than was ob-

tained earlier (see **Figure 8**).

It shows that the residues A8 and U9 in the open cav-



Figure 6. Residues A8 and U9 of the predicted structures have been highlighted.



Figure 7. Bond between the SECIS element and the residues A8 and U9 of the predicted structures is shown.




Figure 8. Showing docked complexes with and without the residues A8 and U9 of the predicted structures and the respective E-values.

ity are an important part of the stable binding of the human Sec tRNA^{Sec} and HIV SECIS elements.

REFERENCES

- [1] V. N. Gladyshev, T. C. Stadtman, D. L. Hatfield and K. T. Jeang, "Levels of Major Selenoproteins in T Cells Decrease during HIV Infection and Low Molecular Mass Selenium Compounds Increase," *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 96, No. 3, 1999, pp. 835-839. [doi:10.1073/pnas.96.3.835](https://doi.org/10.1073/pnas.96.3.835)
- [2] B. Moghadaszadeh and A. H. Beggs, "Selenoproteins and Their Impact on Human Health through Diverse Physiological Pathways," *Physiology*, Vol. 21, No. 5, 2006, pp. 307-315. [doi:10.1152/physiol.00021.2006](https://doi.org/10.1152/physiol.00021.2006)
- [3] B. M. Dworkin, "Selenium Deficiency in HIV Infection and the Acquired Immunodeficiency Syndrome (AIDS)," *Chemico-Biological Interactions*, Vol. 9, No. 2-3, 1994, pp. 181-186. [doi:10.1016/0009-2797\(94\)90038-8](https://doi.org/10.1016/0009-2797(94)90038-8)
- [4] J. Lu and A. Holmgren, "Selenoproteins," *Journal of Biological Chemistry*, Vol. 284, No. 2, 2009, pp.723-727. [doi:10.1074/jbc.R800045200](https://doi.org/10.1074/jbc.R800045200)
- [5] S. C. Gamble, A. Wiseman and P. S. Goldfarb, "Selenium-Dependent Glutathione Peroxidase and Other Selenoproteins: Their Synthesis and Biochemical Roles," *Journal of Chemical Technology and Biotechnology*, Vol. 68, No.2, 1997, pp. 123-134. [doi:10.1002/\(SICI\)1097-4660\(199702\)68:2<123::AID-JC TB641>3.0.CO;2-O](https://doi.org/10.1002/(SICI)1097-4660(199702)68:2<123::AID-JC TB641>3.0.CO;2-O)
- [6] X. M. Xu, B. A. Carlson, Y. Zhang, H. Mix, G. V. Kryukov, R. S. Glass, M. J. Berry, V. N. Gladyshev and D. L. Hatfield, "New Developments in Selenium Biochemistry: Selenocysteine Biosynthesis in Eukaryotes and Archaea," *Biological Trace Element Research*, Vol. 119, No. 3, 2007, pp. 234-241. [doi:10.1007/s12011-007-8003-9](https://doi.org/10.1007/s12011-007-8003-9)
- [7] J. M. Coffin, S. H. Hughes and H. E. Varmus, "Retroviruses," Cold Spring Harbor Laboratory Press, New York, 1997.
- [8] A. D. Frankel and J. A. Young, "HIV-1: Fifteen Proteins and an RNA," *Annual Review of Biochemistry*, Vol. 67, No. 1, 1998, pp. 1-25. [doi:10.1146/annurev.biochem.67.1.1](https://doi.org/10.1146/annurev.biochem.67.1.1)
- [9] C. K. Damgaard, E. S. Andersen, B. Knudsen, J. Gorodkin and J. Kjems, "RNA Interactions in the 5' Region of the HIV-1 Genome," *Journal of Molecular Biology*, Vol. 336, No. 2, 2004, pp. 369-379. [doi:10.1016/j.jmb.2003.12.010](https://doi.org/10.1016/j.jmb.2003.12.010)
- [10] S. P. Goff, "Host Factors Exploited by Retroviruses," *Nature Reviews Microbiology*, Vol. 5, No. 4, 2007, pp. 253-263.
- [11] K. A. Wilkinson, R. J. Gorelick, S. M. Vasa, N. Guex, A. Rein, D. H. Mathews, M. C. Giddings and K. M. Weeks, "High-Throughput SHAPE Analysis Reveals Structures in HIV-1 Genomic RNA Strongly Conserved across Distinct Biological States," *PLoS Biology*, Vol. 6, No. 4, 2008, pp. 883-899. [doi:10.1371/journal.pbio.0060096](https://doi.org/10.1371/journal.pbio.0060096)
- [12] J. M. Watts, K. K. Dang, R. J. Gorelick, C. W. Leonard, J. W. Bess, R. Swanstrom Jr., C. L. Burch and K. M. Weeks, "Architecture and Secondary Structure of an Entire HIV-1 RNA Genome," *Nature*, Vol. 460, No. 7256, 2009, pp. 711-716. [doi:10.1038/nature08237](https://doi.org/10.1038/nature08237)
- [13] L. Zhao, A. G. Cox, J. A. Ruzicka, A. A. Bhat, W. Zhang and E. W. Taylor, "Molecular Modeling and *in Vitro* Activity of an HIV-1-Encoded Glutathione Peroxidase," *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 97, No. 12, 2000, pp. 6356-6361. [doi:10.1073/pnas.97.12.6356](https://doi.org/10.1073/pnas.97.12.6356)
- [14] G. Leslie, "Potential SECIS Elements in HIV-1 Strain HXB2," *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, Vol. 17, No. 5, 1998, pp. 398-403. [doi:10.1097/00042560-199804150-00003](https://doi.org/10.1097/00042560-199804150-00003)
- [15] Y. Zhang and V. N. Gladyshev, "An Algorithm for Identification of Bacterial Selenocysteine Insertion Sequence Elements and Selenoprotein Genes," *Bioinformatics*, Vol. 21, No. 11, 2005, pp. 2580-2589. [doi:10.1093/bioinformatics/bti400](https://doi.org/10.1093/bioinformatics/bti400)
- [16] M. Zuker, "Mfold Web Server for Nucleic Acid Folding and Hybridization Prediction," *Nucleic Acids Research*, Vol. 31, No. 13, 2003, pp. 3406-3415. [doi:10.1093/nar/gkg595](https://doi.org/10.1093/nar/gkg595)
- [17] Y. Ding and C. E. Lawrence, "A Bayesian Statistical Algorithm for RNA Secondary Structure Prediction," *Computers & Chemistry*, Vol. 23, No. 3-4, 1999, pp. 387-400. [doi:10.1016/S0097-8485\(99\)00010-8](https://doi.org/10.1016/S0097-8485(99)00010-8)
- [18] Y. Itoh, S. Chiba, S. Sekine and S. Yokoyama, "Crystal Structure of Human Selenocysteine tRNA," *Nucleic Acids Research*, Vol. 37, No. 18, 2009, pp. 6259-6268. [doi:10.1093/nar/gkp648](https://doi.org/10.1093/nar/gkp648)